Despite these advances, there are still unmet needs for continuous blockade with new HER2-targeted agents, since advanced breast cancer is still an incurable disease and there is no standard of care for patients who have received two lines of anti-HER2 regimens in China and those who have received T-DXd globally. The gene discussed is ERBB2; the disease is breast cancer.